NIH-U01: International Collaborations in Infectious Diseases Research


This program supports research requiring access to populations of infected human and/or other mammalian hosts, parasites, and/or vectors limited or unavailable in the U.S. and other developed countries. Therefore, the majority of research supported under the ICIDR program must be conducted at one or more foreign sites with an emphasis on field and clinical studies of endemic diseases. Characteristics of the proposed research should include the following:

1. Research on infectious diseases (except HIV/AIDS), including emerging infections, that are of importance and/or interest to the foreign collaborating country, including one or more of the following:

– Research addressing infectious diseases of significant public health importance within the collaborating foreign country that cannot be addressed in the U.S or other developed countries, such as (but not limited to): dengue, tuberculosis, trachoma, Nipah, and malaria. Research may also include studies of vector-borne pathogens for which the vector is not endemic to the U.S. and colonies are not available in U.S. labs.

– Research addressing neglected or understudied infectious diseases where little may be known about the impact on public health in areas outside developed countries, and where there is reason to believe that these infections contribute to the disease burden in the foreign country, including recently emerging diseases, such as MERS-CoV.

– Research on infectious diseases in special populations or in the setting of co-infections that are particular to the eligible country/countries. Examples include but are not limited to: pertussis, pneumonia, and diarrhea in infants.

– For diseases that can be studied within U.S. populations, research must focus on aspects of disease or on populations that are not available in the U.S. Examples include but are not limited to: vector-pathogen-reservoir interactions, regional epidemiology, Chagas disease, congenital syphilis, influenza in tropical areas and hepatitis. Also included are emerging and unique diseases that are rare in the US, such as those caused by the viral hemorrhagic fever viruses.

2. Research may focus on more than one organism/infectious disease (e.g. diarrheal or respiratory diseases), including co-infections and microbiome studies, provided a strong rationale is given.

3. Within the guidelines above, studies may be proposed on any aspect of infectious diseases, including, but not limited to: the epidemiology, natural history of disease, pathogenesis, and immunopathogenesis; epidemiologic or natural history studies to define the incidence, clinical presentations, time course, and outcomes of diseases; studies of correlates of immunity to infectious diseases in patients with little or no disease; identification of resistance patterns; identification of biomarkers that can be used to develop diagnostics, targets for therapy or vaccines; characterization of susceptible cohorts for a particular pathogen; and pilot or feasibility studies in preparation for larger studies.

4. Development and/or evaluation of point-of-care or improved diagnostics is encouraged. Evaluation of new diagnostics is allowed as long treatment/care is determined by standard, accepted procedures and results of the evaluated diagnostic for an individual are not reported back to the treating physician and do not impact care. Routine diagnosis, treatment, and care must be provided outside of the proposed research project.

5. Development of immunological, microbiological, biostatistical, epidemiological, data management and clinical research capacity at the endemic sites is strongly encouraged. Multidisciplinary collaborations are encouraged to ensure the appropriate breadth of scientific expertise in contributing fields, including but not limited to: infectious diseases, biochemistry, immunology, genetics, pharmacology, molecular biology, microbiology, zoology, and medical entomology.

Termini IISPV

1- Declaration of interest: IISPV’s deadline: January 15th, 2014(

2- NIH Register; create PI account(s); affiliate PI account to IISPV, etc.

3- Letter of Intent: IISPV’s deadline: January 31st, 2014

4. Full proposal: IISPV’s deadline: March 1st, 2014.



Termini Oficial

1. Letter of Intent: Official deadline: February 7th, 2014.

2. Full appplication: Official deadline: March 7th, 2014.

Estàs interessat?

Omple el següent formulari per rebre més informació: